

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 5

**Complete if Known**

Application Number	09/882,621
Filing Date	June 15, 2001
First Named Inventor	Houtzager et al.
Group Art Unit	1648
Examiner Name	M. Hill
Attorney Docket Number	2578-49571US

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
MA	1	BALINT et al., Antibody engineering by parsimonious mutagenesis, Gene, 1993, pp. 109-18, Vol. 137.	
	2	BARBAS III et al., In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity, Proc. Natl. Acad. Sci., April 1994, pp. 3809-13, Vol. 91, USA.	
	3	BASS et al., Hormone Phage: An Enrichment Method for Variant Proteins With Altered Binding Properties, Proteins: Structure, Function, and Genetics, 1990, pp. 309-14, Vol. 8.	
	4	BEEKWILDER et al., A phagemid vector using the E. coli phage shock promoter facilitates phage display of toxic proteins, Gene, 1999, pp. 23-31, Vol. 228.	
	5	BEREK et al., Mutation Drift and Repertoire Shift in the Maturation of the Immune Response, Immunological Reviews, 1987, pp. 23-41, No. 96.	
	6	BURTON et al., Human Antibodies from Combinatorial Libraries, Advances in Immunology, pp. 191-280, Vol. 57.	
	7	CHATELLIER et al., Interdomain interactions within the gene 3 protein of filamentous phage, FEBS Letters, 1999, pp. 371-74, Vol. 463.	
	8	CRISSMAN et al., Gene-III Protein of Filamentous Phages: Evidence for a Carboxyl-Terminal Domain with a Role in Morphogenesis, Virology, 1984, pp. 445-55, Vol. 132.	
	9	CWIRLA et al., Peptides on phage: A vast library of peptides for identifying ligands, Proc. Natl. Acad. Sci., August 1990, pp. 6378-82, Vol. 87.	
	10	DE KRUIF et al., Selection and Application of Human Single Chain Fv Antibody Fragments from a Semi-synthetic Phage Antibody Display Library with Designed CDR3 Regions, J. Mol. Biol., 1995, pp. 97-105, Vol. 248.	
	11	DE KRUIF et al., Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library, Proc. Natl. Acad. Sci., April 1995, pp. 3938-42, Vol. 92, USA.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)


Sheet 3 of 5


**Complete if Known**

Application Number	09/882,621
Filing Date	June 15, 2001
First Named Inventor	Houtzager et al.
Group Art Unit	1648
Examiner Name	M. Hill
Attorney Docket Number	2578-4957LIS

RECEIVED  
SEP 22 2003  
TECH CENTER 1600/2900

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	-	DENG et al., Interaction of the Globular Domains of pIII Protein of Filamentous Bacteriophage fd with the F-Pilus of Escherichia coli, Virology, 1999, pp. 271-77, Vol. 253.	
	-	DEVLIN et al., Random Peptide Libraries: A Source of Specific Protein Binding Molecules, Science, July 27, 1990, pp. 404-06, Vol. 249.	
	-	DUENAS et al., Clonal Selection and Amplification of Phage Displayed Antibodies by Linking Antigen Recognition and Phage Replication, Bio/Technology, October 1994, pp. 999-1002, Vol. 12.	
	-	DUENAS et al., Novel helper phage design: intergenic region affects the assembly of bacteriophages and the size of antibody libraries, FEMS Microbiology Letters, 1995, pp. 317-22, Vol. 125.	
	-	FELICI et al., Mimicking of discontinuous epitopes by phage-displayed peptides, II. Selection of clones recognized by a protective monoclonal antibody against the Bordetella pertussis toxin from phage peptide libraries, Gene, 1993, pp. 21-27, Vol. 128.	
	-	HAWKINS et al., Selection of Phage Antibodies by Binding Affinity, Mimicking Affinity Maturation, J. Mol. Biol., 1992, pp. 889-96, Vol. 226.	
	-	HOLLIGER et al., A conserved infection pathway for filamentous bacteriophages is suggested by the structure of the membrane penetration domain of the minor coat protein g3p from phage fd, Structure, 1997, pp. 265-75, Vol. 5, No. 2.	
	-	HOOGENBOOM et al., Designing and optimizing library selection strategies for generating high-affinity antibodies, TIB Tech, February 1997, pp. 62-70, Vol. 15.	
	-	KREBBER et al., Co-selection of cognate antibody-antigen pairs by selectively-infective phages, FEBS Letters, 1995, pp. 227-31, Vol. 377.	
	-	KREBBER et al., Selectively-infective Phage (SIP): A Mechanistic Dissection of a Novel in vivo Selection for Protein-ligand Interactions, J. Mol. Biol. 1997, pp. 607-18, Vol. 268.	
-	KRISTENSEN et al., Proteolytic selection for protein folding using filamentous bacteriophages, Folding & Design, pp. 321-28, Vol. 3, No. 5.		

Examiner  
Signature

Date  
Considered

12/5/01

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 5

**Complete if Known**

Application Number	09/882,621
Filing Date	June 15, 2001
First Named Inventor	Houtzager et al.
Group Art Unit	1648
Examiner Name	M. Hill
Attorney Docket Number	2578-4957US

RECEIVED  
SEP 22 2003  
TECH CENTER 1800/2900**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
NO		LOW et al., Mimicking Somatic Hypermutation: Affinity Maturation of Antibodies Displayed on Bacteriophage Using a Bacterial Mutator Strain, J. Mol. Biol., 1996, pp. 359-68, Vol. 260.	
		LUBKOWSKI et al., The structural basis of phage display elucidated by the crystal structure of the N-terminal domains of g3p, Nature Structural Biology, February 1998, pp. 140-47, Vol. 5, No. 2.	
		LUBKOWSKI et al., Filamentous phage infection: crystal structure of g3p in complex with its coreceptor, the C-terminal domain of TolA, Structure, 1999, pp. 711-22, Vol. 7, No. 6.	
		LUZZAGO et al., Mimicking of discontinuous epitopes by phage-displayed peptides, I. Epitope mapping of human H ferritin using a phage library of constrained peptides, Gene, 1993, pp. 51-57, Vol. 128.	
		LOPEZ et al., Morphogenesis of Filamentous Bacteriophage f1: Orientation of Extrusion and Production of Polyphage, Virology, 1983, pp. 177-93, Vol. 127.	
		MODEL et al., The Escherichia coli phage-shock-protein (psp) operon, Molecular Microbiology, 1997, pp. 255-61, Vol. 24, No. 2.	
		NELSON et al., Filamentous Phage DNA Cloning Vectors: A Noninfective Mutant with a Nonpolar Deletion in Gene III, Virology, 1981, pp. 338-50, Vol. 108.	
		NILSSON et al., The Phage Infection Process: a Functional Role for the Distal Linker Region of Bacteriophage Protein 3, Journal of Virology, May 2000, pp. 4229-35, Vol. 74.	
		PRATT et al., Conditional Lethal Mutants of the Small Filamentous Coliphage M13. II. Two Genes for Coat Proteins, Virology, 1969, pp. 42-53, Vol. 39.	
		RAKONJAC et al., Filamentous phage infection-mediated gene expression: construction and propagation of the gIII deletion mutant helper phage R408d3, Gene, 1997, pp. 99-103, Vol. 198.	
		RAKONJAC et al., Roles of pIII in Filamentous Phage Assembly, J. Mol. Biol. 1998, pp. 25-41, Vol. 282.	

Examiner  
SignatureDate  
Considered

12/5/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 5

**Complete if Known**

Application Number	09/882,621
Filing Date	June 15, 2001
First Named Inventor	Houtzager et al.
Group Art Unit	1648
Examiner Name	M. Hill
Attorney Docket Number	2578-4957US

**RECEIVED**  
SEP 22 2003  
TECH CENTER 1600/2900**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
WJH		RIECHMANN et al., The C-Terminal Domain of TolA Is the Coreceptor of Filamentous Phage Infection of E. coli, Cell, July 25, 1997, pp. 351-60, Vol. 90.	
		RONDOT et al., A helper phage to improve single-chain antibody presentation in phage display, Nature Biotech, pp. 75-78, Vol. 19.	
		RUSSEL et al., Genetic Analysis of the Filamentous Bacteriophage Packaging Signal and of the Proteins That Interact with It, Journal of Virology, Aug. 1989, pp. 3284-95, Vol. 63, No. 8.	
		SMITH, Filamentous Fusion Phage: Novel Expression Vectors That Display Cloned Antigens on the Virion Surface, Science, June 14, 1985, pp. 1315-17, Vol. 228.	
		SPADA et al., Selectively Infective Phages (SIP), Biol. Chem., June 1997, pp. 445-56, Vol. 378.	
		VAUGHAN et al., Human antibodies by design, Nature Biotechnology, June 1998, pp. 535-39, Vol. 16.	
		WINTER et al., Man-made antibodies, Nature, January 24, 1991, pp. 293-99, Vol. 349.	
		YANG et al., CDR Walking Mutagenesis for the Affinity Maturation of a Potent Human Anti-HIV-1 Antibody into the Picomolar Range, J. Mol. Biol., 1995, pp. 392-403.	
		PCT International Search Report, PCT/NL02/00391, dated November 25, 2002, 3 pages.	

Examiner  
SignatureDate  
Considered

12/5/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.